Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong ...

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

Torrent Pharmaceuticals added 1.53% to Rs 3,292.95 after the company's consolidated net profit increased 10.91% to Rs 498 crore in Q4 FY25 as against Rs 449 crore posted in Q4 FY24.

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Prabhudas Lilladher recommended accumulate rating on Torrent Pharmaceuticals with a target price of Rs 3670 in its research ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Jefferies recommends Buy on DLF, CMS Info Systems, and Torrent Pharma, citing strong fundamentals and growth prospects. Check ...

Aman Mehta, third generation of Torrent Group’s founder Mehta family, was on Tuesday appointed Managing Director of the ...

Net Sales at Rs 2,433.00 crore in March 2025 up 13.53% from Rs. 2,143.00 crore in March 2024. Quarterly Net Profit at Rs. 474.00 crore in March 2025 up 15.61% from Rs. 410.00 crore in March 2024.

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Torrent Pharmaceuticals posted a steady set of numbers in the fourth quarter, reinforcing confidence in its growth trajectory ...